LOWER VACCINE DOSE ASSOCIATES WITH ANTI-CSP ANTIBODY DURABILITY AND FUNCTION: PHASE I TRIALS OF R21/MATRIX-M IN EUROPE AND AFRICA

2019 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []